ID: h-11ba42d0-cel
Hypothesis
APOE4-Specific Lipidation Enhancement Therapy (Cell-Cell Communication)
neurodegeneration
EvidencePending (0%)📖 4 cit🗣 1 debates✓ 4 support✗ 2 oppose
⚠ Thin Description Senate Quality Gates →
🧪 Overview
No data yet for this section.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["APOE4 Isoform<br/>Structural Instability"]
B["Impaired Lipid Loading<br/>Reduced Cholesterol Efflux"]
C["LRP1 Reduced Binding<br/>BBB Clearance Deficit"]
D["Amyloid-beta<br/>Accumulation"]
E["Synaptic Dysfunction<br/>Membrane Disruption"]
F["Neurodegeneration<br/>Cognitive Decline"]
G["APOE3 Comparison<br/>Normal Lipidation"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"protective"| C
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix4 supports0 contradicts
Supports
LXR agonists restore ApoE lipidation in glia and reduce tau/lipid accumulation in ApoE4 mice, providing direct proof-of-concept that lipidation enhancement is therapeutically tractable.
Supports
ApoE4 impairs ABCA1 membrane trafficking in astrocytes, reducing cholesterol efflux and limiting APOE lipidation — the mechanistic deficit targeted by lipidation enhancement therapy.
Supports
CSF lipoprotein-mediated cholesterol delivery to neurons is impaired in Alzheimer brain, implicating glial lipid efflux pathways as a disease-modifiable target.
Supports
Inhibiting ACAT1/SOAT1 cholesterol esterification in ApoE4 mice shifts brain lipid homeostasis and reduces neurodegeneration-associated markers.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — APOE
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for APOE from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for APOE.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.2315
Events (7d)
0
Price History
▲5.2%💾 Resource Usage
LLM Tokens
862
$0.0026
Total Cost
$0.0026
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF 10-month-old APOE4/4 knock-in mice receive daily oral LXRβ agonist (GW3965, 10mg/kg) for 5 months, THEN cortical amyloid plaque burden will decrease by ≥40% compared to vehicle-treated APOE4/4 mice | ≥40% reduction in Thioflavin-S+ plaque area fraction in cortex of treated vs. control mice | — no observation — | pending | 0.35 |
| IF human iPSC-derived astrocytes homozygous for APOE4 are treated with an LXRβ-selective agonist (e.g., GSK2033 at 1μM) for 72 hours, THEN conditioned medium APOE4 lipidation will increase by ≥30% rel | ≥30% increase in lipidated APOE4 species (band density ratio) in treatment vs. vehicle condition | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF human iPSC-derived astrocytes homozygous for APOE4 are treated with an LXRβ-selective agonist (e.g., GSK2033 at 1μM) for 72 hours, THEN conditioned medium APOE4 lipidation will increase by ≥30% relative to vehicle-treated APOE4 astrocytes, as quantified by density shift on native PAGE.
Predicted outcome: ≥30% increase in lipidated APOE4 species (band density ratio) in treatment vs. vehicle condition
Falsification: No significant increase or a decrease in APOE4 lipidation following LXRβ agonist treatment (p>0.05, Student's t-test)
pendingconf 35%
IF 10-month-old APOE4/4 knock-in mice receive daily oral LXRβ agonist (GW3965, 10mg/kg) for 5 months, THEN cortical amyloid plaque burden will decrease by ≥40% compared to vehicle-treated APOE4/4 mice, assessed by Thioflavin-S stereology.
Predicted outcome: ≥40% reduction in Thioflavin-S+ plaque area fraction in cortex of treated vs. control mice
Falsification: No significant reduction (or increase) in amyloid plaque burden in treated mice after 5-month intervention (p>0.05, Mann-Whitney U test)
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.